Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin’s lymphoma: initial experience

被引：0
|
作者：
Maren Bienert
Ingrid Reisinger
Stefanie Srock
Beatrice I Humplik
Christel Reim
Thomas Kroessin
Norbert Avril
Antonio Pezzutto
Dieter L Munz
机构：
[1] Charité—Universitätsmedizin Berlin,Clinic for Nuclear Medicine
[2] Charité—Universitätsmedizin Berlin,Department of Haematology and Oncology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2005年 / 32卷
关键词：
Non-Hodgkin’s lymphoma; Radioimmunotherapy; I-rituximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1225 / 1233
页数：8
相关论文
共 50 条
  • [31] SUVmax predicts survival in patients with diffuse large B-cell lymphoma who received radioimmunotherapy using 131I-rituximab as consolidation therapy
    Choi, J.
    Lim, I.
    Byun, B.
    Kim, B.
    Choi, C.
    Lim, S.
    Shin, D.
    Kang, H.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S777 - S778
  • [32] B cell non-Hodgkin's lymphoma: rituximab safety experience
    Mohrbacher, A
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 3) : S19 - S25
  • [33] B cell non-Hodgkin's lymphoma: rituximab safety experience
    Ann Mohrbacher
    Arthritis Research & Therapy, 7
  • [34] Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
    Leahy, Michael F.
    Turner, J. Harvey
    BLOOD, 2011, 117 (01) : 45 - 52
  • [35] Radioimmunotherapy: A novel treatment modality for B-cell non-Hodgkin's lymphoma
    Juweid, M
    DeNardo, GL
    Graham, M
    Vose, J
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (05) : 673 - 674
  • [36] Radioimmunotherapy: A new treatment modality for B-cell non-Hodgkin's lymphoma
    Ghobrial, Irene
    Witzig, Thomas
    ONCOLOGY-NEW YORK, 2004, 18 (05): : 623 - 630
  • [37] The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma
    Witzig, TE
    SEMINARS IN ONCOLOGY, 2000, 27 (06) : 74 - 78
  • [38] Radioimmunotherapy in relapsed or refractory B-cell non-hodgkin's lymphoma with I-131-labeled chimericanti CD20 C2B8 (I-131 rituximab)
    Kang, H. J.
    Park, Y. H.
    Kim, S.
    Cheon, G. J.
    Choi, C. W.
    Lim, S. M.
    Lee, S. S.
    Na, I. I.
    Ryoo, B. Y.
    Yang, S. H.
    Kim, W. S.
    Kim, K. H.
    Bang, S. M.
    Yuh, Y. J.
    Nam, S. H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 108 - 109
  • [39] Investigation of change in residence-time in repeated radioimmunotherapy using I-131 rituximab for non-hodgkin's lymphoma
    Lim, S.
    Park, J.
    Kim, K.
    Kang, H.
    Choi, T.
    Kim, J.
    Woo, S.
    Kim, J.
    Kim, B.
    Cheon, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S292 - S292
  • [40] Rituximab in B-cell disorders other than non-Hodgkin's lymphoma
    Bosly, A
    Keating, MJ
    Stasi, R
    Bradstock, K
    ANTI-CANCER DRUGS, 2002, 13 : S25 - S33
12345